Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2FGRT)

• Drug Name: Clavulanate Drug Info
• Synonyms: Clavulansaeure; Clavulox; Acide clavulanique; Acido clavulanico; Acidum clavulanicum; CLAVULANIC ACID; Clavulansaeure [INN]; Clavulinic Acid; Sodium Clavulanate; Antibiotic MM 14151; MM 14151; Acide clavulanique [INN-French]; Acido clavulanico [INN-Spanish]; Acidum clavulanicum [INN-Latin]; BRL-14151; Clavulanic acid (INN); Clavulanic acid [BAN:INN]; Clavulox (TN); MM-14151; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Z)-(2R,5R)-3-(2-Hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3008-B; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2alpha,3Z,5alpha))

Indication

Disease Entry	ICD 11	Status	REF
Bacteremia	1A73	Approved	[1]
Bacterial infection	1A00-1C4Z	Approved	[2]
Staphylococcal pneumonia		Approved	[1]
Staphylococcus aureus infection		Approved	[1]
Streptococcal pneumonia		Approved	[1]
Urinary tract infection	GC08	Approved	[1]
Pneumonia due to Klebsiella pneumoniae	CA40.03	Investigative	[1]
Sinusitis	CA0A.Z	Investigative	[1]

• Therapeutic Class: Antibiotics
• Cross-matching ID:
  PubChem CID: 5280980
  ChEBI ID: CHEBI:48947
  CAS Number: CAS 58001-44-8
  TTD Drug ID: DM2FGRT

Molecule-Related Drug Atlas

Drug(s) Targeting Staphylococcus Beta-lactamase (Stap-coc blaZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tazobactam	DM3XNUI	Appendicitis	DB10	Approved	[7]
CAZ AVI	DMPG4OM	Serious infection	1H0Z	Phase 3	[8]
Enmetazobactam	DMZKTYJ	Urinary tract infection	GC08	Phase 3	[9]
Vaborbactam	DMDCFXJ	Urinary tract infection	GC08	Phase 3	[10]
MK-7655	DMLMV0O	Bacterial infection	1A00-1C4Z	Phase 2	[11]
CXL	DM3JFZ2	Methicillin-resistant staphylococci infection	1A00-1A09	Phase 2	[12]
RASV-Sp	DM4VTX6	Streptococcus infection	1B53	Phase 1	[13]
ME-1071	DMEMQ5J	Bacterial infection	1A00-1C4Z	Phase 1	[14]
OP-0595	DMECVP9	Bacterial infection	1A00-1C4Z	Phase 1	[15]
VNRX-5133	DMNZ6XH	Bacterial infection	1A00-1C4Z	Phase 1	[16]

Drug(s) Affected By C-C chemokine receptor type 9 (CCR9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[6]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[17]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[18]
QUERCITRIN	DM1DH96	Discovery agent	N.A.	Investigative	[19]

Drug(s) Affected By C-C chemokine receptor type 4 (CCR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[6]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[20]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[21]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[22]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[23]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[24]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[25]
KOJIC ACID	DMP84CS	Discovery agent	N.A.	Investigative	[26]
Sulforaphane	DMQY3L0	Skin disease	EA00-EM0Z	Investigative	[27]

Drug(s) Affected By HLA class I histocompatibility antigen, A alpha chain (HLA-A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[28]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[29]
Allopurinol	DMLPAOB	Gout	FA25	Approved	[30]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[31]
Ticlopidine	DMO946V	Acute coronary syndrome	BA41	Approved	[32]
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[33]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[35]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[35]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[35]

Drug(s) Affected By C-X-C chemokine receptor type 3 (CXCR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[6]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[22]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[37]
MLN4924	DMP36KD	Myelodysplastic syndrome	2A37	Phase 3	[38]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[39]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[40]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[24]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[41]
Nickel chloride	DMI12Y8	Discovery agent	N.A.	Investigative	[39]

Drug(s) Affected By Stearoyl-CoA desaturase (SCD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[42]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[42]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[43]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[45]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[42]
Fructose	DM43AN2	Vomiting	MD90	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[47]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[42]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[48]

Drug(s) Affected By Proepiregulin (EREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[49]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[5]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[50]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[5]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[53]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[5]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[5]

Drug(s) Affected By Aldo-keto reductase family 1 member B10 (AKR1B10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[54]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[55]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[56]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[57]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[58]
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[59]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[60]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[62]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[63]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[63]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[64]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[62]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[63]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[65]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[62]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[66]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[62]

Drug(s) Affected By Fibroblast growth factor 19 (FGF19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[43]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[67]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[68]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[69]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[70]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[71]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[72]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[67]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[73]

Drug(s) Affected By Glutathione reductase, mitochondrial (GSR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[74]
Ketoprofen	DMRKXPT	Bursitis		Approved	[6]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[75]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[76]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[77]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[68]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[78]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[79]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[80]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[75]

Drug(s) Affected By Interleukin-1 alpha (IL1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[81]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[5]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[5]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[82]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[43]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[83]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[5]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[84]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[5]

Drug(s) Affected By Interleukin-1 beta (IL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[85]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[86]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[87]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[5]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[88]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[5]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[89]
Selenium	DM25CGV	N. A.	N. A.	Approved	[90]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[91]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[92]

Drug(s) Affected By Antileukoproteinase (SLPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[5]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[5]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[50]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[5]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[5]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[5]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[5]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[5]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[5]

Drug(s) Affected By Alcohol dehydrogenase 1A (ADH1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[93]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[94]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[96]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[97]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[64]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[98]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[99]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[100]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[101]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[102]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[5]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[5]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[103]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[5]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[104]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[103]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[5]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[105]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[106]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[107]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[108]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[109]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[86]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[5]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[88]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[110]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[5]

Drug(s) Affected By Glucose-6-phosphate 1-dehydrogenase (G6PD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[111]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[6]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[112]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[113]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[76]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[114]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[115]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[116]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[117]

Drug(s) Affected By Glutathione peroxidase 2 (GPX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[118]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[68]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[55]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[120]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[121]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[122]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[58]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[123]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[124]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[125]
Methysergide	DM1EF73	Migraine	8A80	Approved	[65]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[126]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[65]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[68]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[127]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[128]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[129]

Drug(s) Affected By Cytochrome P450 7A1 (CYP7A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[130]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[126]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[131]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[132]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[84]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[69]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[122]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[133]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[131]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[134]

Drug(s) Affected By Transketolase (TKT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[135]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[136]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[115]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[58]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[137]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[138]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[139]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[140]

Drug(s) Affected By Sterol regulatory element-binding protein 1 (SREBF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[52]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[6]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[94]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[141]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[142]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[68]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[143]
Vemurafenib	DM62UG5	Melanoma	2C30	Approved	[144]

Drug(s) Affected By NADP-dependent malic enzyme (ME1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[118]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Selenium	DM25CGV	N. A.	N. A.	Approved	[135]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[115]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[145]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[146]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[146]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[147]

Drug(s) Affected By Lanosterol synthase (LSS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[148]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[148]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[148]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[148]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[68]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[55]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[149]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[148]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[148]

Drug(s) Affected By Glutamate--cysteine ligase catalytic subunit (GCLC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[118]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[150]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[151]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[152]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[153]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[154]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[155]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[156]

Drug(s) Affected By Glutamate--cysteine ligase regulatory subunit (GCLM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[118]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[157]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[158]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[115]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[79]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[100]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[145]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[159]
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[160]

Drug(s) Affected By Tumor necrosis factor-inducible gene 6 protein (TNFAIP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Selenium	DM25CGV	N. A.	N. A.	Approved	[90]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[163]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[5]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[5]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[5]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[5]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[41]

Drug(s) Affected By Sterol 26-hydroxylase, mitochondrial (CYP27A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[164]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[68]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[165]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[166]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[167]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[97]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[168]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[169]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]

Drug(s) Affected By Mevalonate kinase (MVK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[135]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[170]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[68]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[55]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[115]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[97]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[171]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[99]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[172]

Drug(s) Affected By Interleukin-24 (IL24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[81]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[5]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[86]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[5]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[173]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[114]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[5]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[5]

Drug(s) Affected By Hepatic sodium/bile acid cotransporter (SLC10A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[132]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[55]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[174]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[122]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[175]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[97]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[176]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[55]

Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[130]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[148]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[113]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[54]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[148]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[149]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[177]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[148]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[132]

Drug(s) Affected By Organic solute transporter subunit alpha (SLC51A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[50]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[126]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[68]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[34]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[178]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[67]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[179]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[180]

Drug(s) Affected By ATP-binding cassette sub-family C member 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lopinavir	DMITQS0	Human immunodeficiency virus infection	1C62	Approved	[181]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[182]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[183]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[184]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[185]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[186]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[67]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[187]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[188]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[189]

Drug(s) Affected By ATP-binding cassette sub-family G member 5 (ABCG5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[190]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[67]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[180]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[97]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[64]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[172]
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[67]

Drug(s) Affected By 7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (CYP8B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[67]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[68]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[97]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[168]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[191]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[192]

Drug(s) Affected By Cystine/glutamate transporter (SLC7A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[118]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[5]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[157]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[5]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[103]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[193]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[194]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[5]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[129]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Staphylococcus Beta-lactamase (Stap-coc blaZ)	TTHI19T	BLAC_STAAU	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (CYP8B1)	OTRI4UR1	CP8B1_HUMAN	Gene/Protein Processing	[4]
Alcohol dehydrogenase 1A (ADH1A)	OTTS983E	ADH1A_HUMAN	Gene/Protein Processing	[4]
Aldo-keto reductase family 1 member B10 (AKR1B10)	OTOA4HTH	AK1BA_HUMAN	Gene/Protein Processing	[4]
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[5]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Gene/Protein Processing	[4]
ATP-binding cassette sub-family G member 5 (ABCG5)	OT1OMY93	ABCG5_HUMAN	Gene/Protein Processing	[4]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[4]
C-C chemokine receptor type 4 (CCR4)	OT68KZ9B	CCR4_HUMAN	Drug Response	[6]
C-C chemokine receptor type 9 (CCR9)	OT5FSOD8	CCR9_HUMAN	Drug Response	[6]
C-X-C chemokine receptor type 3 (CXCR3)	OTIGS220	CXCR3_HUMAN	Drug Response	[6]

References

• [1] Clavulanate FDA Label
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 065063.
• [3] A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
• [4] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [5] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [6] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [7] Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
• [8] NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
• [9] Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
• [10] Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
• [11] Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
• [12] Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
• [13] WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.
• [14] Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
• [15] OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86.
• [16] Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo--lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem. 2020 Mar 26;63(6):2789-2801.
• [17] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [18] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [19] Molecular mechanisms of quercitrin-induced apoptosis in non-small cell lung cancer. Arch Med Res. 2014 Aug;45(6):445-54.
• [20] Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003 Jun;81(6):543-55.
• [21] Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006 Dec 1;66(23):11187-93. doi: 10.1158/0008-5472.CAN-06-1274.
• [22] Prenatal arsenic exposure and shifts in the newborn proteome: interindividual differences in tumor necrosis factor (TNF)-responsive signaling. Toxicol Sci. 2014 Jun;139(2):328-37. doi: 10.1093/toxsci/kfu053. Epub 2014 Mar 27.
• [23] Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017 Dec;56(6):1077-1084. doi: 10.1002/mus.25733. Epub 2017 Aug 29.
• [24] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [25] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [26] Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull. 2006 Apr;29(4):655-69.
• [27] Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One. 2014 Jan 22;9(1):e86787. doi: 10.1371/journal.pone.0086787. eCollection 2014.
• [28] HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011 Mar 24;364(12):1134-43. doi: 10.1056/NEJMoa1013297.
• [29] Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010 Mar;11(3):349-56. doi: 10.2217/pgs.09.162.
• [30] Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011 May;21(5):303-7. doi: 10.1097/FPC.0b013e32834282b8.
• [31] A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011 Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4.
• [32] Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008 Feb;8(1):29-33. doi: 10.1038/sj.tpj.6500442. Epub 2007 Mar 6.
• [33] HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013 Jul 9;8(7):e68111. doi: 10.1371/journal.pone.0068111. Print 2013.
• [34] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [35] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [36] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [37] Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci. 2010 Aug;116(2):467-76. doi: 10.1093/toxsci/kfq138. Epub 2010 May 10.
• [38] The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-B activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014 Mar 15;20(6):1576-89. doi: 10.1158/1078-0432.CCR-13-0987.
• [39] Preliminary discovery of novel markers for human cell line activation test (h-CLAT). Toxicol In Vitro. 2021 Aug;74:105154. doi: 10.1016/j.tiv.2021.105154. Epub 2021 Mar 25.
• [40] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [41] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [42] Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
• [43] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [44] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [45] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [46] Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
• [47] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [48] Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol. 2003 May;85(1):1-8. doi: 10.1016/s0960-0760(03)00142-0.
• [49] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [50] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [51] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [52] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [53] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [54] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [55] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [56] Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
• [57] Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
• [58] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [59] Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
• [60] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [61] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
• [62] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [63] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [64] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [65] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [66] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [67] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [68] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [69] Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology. 2011 Feb;53(2):548-57. doi: 10.1002/hep.24047. Epub 2010 Dec 10.
• [70] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [71] Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J Gastroenterol. 2007 Aug 21;13(31):4230-5. doi: 10.3748/wjg.v13.i31.4230.
• [72] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [73] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [74] Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):117-27.
• [75] Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells: Different Mechanisms of THC, CBD, and CB83. Int J Mol Sci. 2020 Aug 1;21(15):5533. doi: 10.3390/ijms21155533.
• [76] Comparison of characteristics of peroxide-conditioned immortal human lens-epithelial cell lines with their murine counterparts. Exp Eye Res. 2004 Sep;79(3):411-7.
• [77] Quercetin modulates Nrf2 and glutathione-related defenses in HepG2 cells: Involvement of p38. Chem Biol Interact. 2012 Jan 25;195(2):154-64.
• [78] Glutathione depletion in antioxidant defense of differentiated NT2-LHON cybrids. Neurobiol Dis. 2007 Mar;25(3):536-44.
• [79] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [80] An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
• [81] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [82] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [83] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [84] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [85] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [86] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [87] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [88] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [89] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [90] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [91] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [92] Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
• [93] An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
• [94] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [95] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [96] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [97] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [98] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [99] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [100] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [101] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [102] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [103] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [104] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [105] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [106] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [107] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [108] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [109] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [110] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [111] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [112] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [113] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [114] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [115] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [116] Isoniazid-induced apoptosis in HepG2 cells: generation of oxidative stress and Bcl-2 down-regulation. Toxicol Mech Methods. 2010 Jun;20(5):242-51. doi: 10.3109/15376511003793325.
• [117] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [118] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [119] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [120] Retinoic acid induces Gpx2 gene expression in MCF-7 human breast cancer cells. J Nutr. 1999 Oct;129(10):1846-54. doi: 10.1093/jn/129.10.1846.
• [121] Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells. J Biol Chem. 2005 Mar 11;280(10):8831-41. doi: 10.1074/jbc.M413730200. Epub 2004 Dec 28.
• [122] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [123] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [124] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [125] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [126] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [127] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [128] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [129] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [130] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [131] The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem. 2004 Mar 5;279(10):8856-61. doi: 10.1074/jbc.M306422200. Epub 2003 Dec 18.
• [132] The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8. doi: 10.1124/mol.105.012104. Epub 2005 May 23.
• [133] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [134] A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol Endocrinol. 2010 Jun;24(6):1151-64.
• [135] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [136] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [137] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [138] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [139] Proteomic analysis of the nucleus accumbens of rats with different vulnerability to cocaine addiction. Neuropharmacology. 2009 Jul;57(1):41-8. doi: 10.1016/j.neuropharm.2009.04.005. Epub 2009 Apr 22.
• [140] Nucleophosmin in the pathogenesis of arsenic-related bladder carcinogenesis revealed by quantitative proteomics. Toxicol Appl Pharmacol. 2010 Jan 15;242(2):126-35. doi: 10.1016/j.taap.2009.09.016. Epub 2009 Oct 7.
• [141] Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice. J Pharmacol Exp Ther. 2018 Mar;364(3):452-461. doi: 10.1124/jpet.117.243105. Epub 2018 Jan 9.
• [142] Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol. 2007 Oct 1;571(2-3):97-105.
• [143] Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
• [144] Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Nat Commun. 2018 Jun 27;9(1):2500. doi: 10.1038/s41467-018-04664-0.
• [145] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [146] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [147] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [148] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [149] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [150] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [151] Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
• [152] Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
• [153] Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter. Free Radic Biol Med. 2002 Mar 1;32(5):386-93. doi: 10.1016/s0891-5849(01)00812-7.
• [154] Glycidamide and cis-2-butene-1,4-dial (BDA) as potential carcinogens and promoters of liver cancer - An in vitro study. Food Chem Toxicol. 2022 Aug;166:113251. doi: 10.1016/j.fct.2022.113251. Epub 2022 Jun 21.
• [155] Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther. 2009 May;8(5):1197-206.
• [156] Hydroquinone increases 5-hydroxymethylcytosine formation through ten eleven translocation 1 (TET1) 5-methylcytosine dioxygenase. J Biol Chem. 2013 Oct 4;288(40):28792-800. doi: 10.1074/jbc.M113.491365. Epub 2013 Aug 12.
• [157] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [158] Essential role of Nrf2 in keratinocyte protection from UVA by quercetin. Biochem Biophys Res Commun. 2009 Sep 11;387(1):109-14. doi: 10.1016/j.bbrc.2009.06.136. Epub 2009 Jul 1.
• [159] An in vitro skin sensitization assay termed EpiSensA for broad sets of chemicals including lipophilic chemicals and pre/pro-haptens. Toxicol In Vitro. 2017 Apr;40:11-25. doi: 10.1016/j.tiv.2016.12.005. Epub 2016 Dec 10.
• [160] Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Exp Biol Med (Maywood). 2013 Aug 1;238(8):932-42. doi: 10.1177/1535370213492689. Epub 2013 Jul 24.
• [161] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [162] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [163] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [164] Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008 Dec;58(12):3675-83.
• [165] PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J Lipid Res. 2007 Feb;48(2):373-84.
• [166] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [167] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [168] Organochloride pesticides modulated gut microbiota and influenced bile acid metabolism in mice. Environ Pollut. 2017 Jul;226:268-276.
• [169] Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
• [170] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [171] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [172] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [173] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [174] Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. J Biol Chem. 2015 Feb 27;290(9):5673-84. doi: 10.1074/jbc.M114.602540. Epub 2014 Dec 30.
• [175] Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006 Oct;34(10):1756-63. doi: 10.1124/dmd.106.010033. Epub 2006 Jul 12.
• [176] Regulation of hepatic drug transporter activity and expression by organochlorine pesticides. J Biochem Mol Toxicol. 2014 Mar;28(3):119-28.
• [177] Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
• [178] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [179] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [180] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [181] Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet Genomics. 2011 Dec;21(12):884-93. doi: 10.1097/FPC.0b013e32834d672b.
• [182] Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther. 2004 Jan;308(1):260-7. doi: 10.1124/jpet.103.057729. Epub 2003 Oct 20.
• [183] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
• [184] Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
• [185] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [186] In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012 Feb 20;25(2):446-53. doi: 10.1021/tx200491f. Epub 2012 Jan 26.
• [187] Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
• [188] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [189] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [190] Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
• [191] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [192] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [193] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [194] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.